Article info

Download PDFPDF

Original research
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis

Authors

  1. Correspondence to Dr Marc R Theoret; Marc.Theoret{at}fda.hhs.gov
View Full Text

Citation

Mulkey F, Theoret MR, Keegan P, et al
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis

Publication history

  • Accepted December 1, 2019
  • First published February 26, 2020.
Online issue publication 
February 26, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.